ABIONYX Pharma S.A. (ABNX)의 가격은 얼마입니까?

ABIONYX Pharma S.A. (ABNX)의 가격은 $2.32입니다.

ABIONYX Pharma S.A. (ABNX)의 시가 총액은 무엇입니까?

ABIONYX Pharma S.A. (ABNX)의 시가 총액은 $98.03M입니다.

ABIONYX Pharma S.A. (ABNX) 액면분할

ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.